Strong Suppression by Mononuclear Leukocytes From Cord Blood of Human Newborns on Maternal Leukocytes Associated With Differences in Sensitivity to Prostaglandin E2*

ABSTRACT: We have tested peripheral mononuclear leukocytes (PML) from the cord blood of newborns, from sera of their mothers, and from sera of nonrelated nonpregnant adult women for sensitivity to suppressive exogenous prostaglandin E₂ (PGE₂). Endogenous PG production was simultaneously inhibited by indomethacin 2.8 μM. The phytohemagglutinin-stimulated (PHA-stimulated) uptake of tritiated thymidine (³H-TdR) by PML from the mothers and the nonpregnant women was suppressed by the exogenous PGE₂ at a concentration of 1.4 × 10^?8 M, 100 times less than the one required to suppress the PML from newborns (1.4 × 10^?6 M). In addition, 1.4 × 10^?7 M or less of PGE₂ reversed the suppression of neonatal PML to stimulation. The maternal PML were reversed into stimulation at 1.4 × 10^?9 of exogenous PGE₂. The amount of endogenous PGE₂ synthesized by 1 × 10⁶ fresh, nonstimulated neonatal PML according to gas chromatography-mass spectrometry assay was 5 ng (1.4 × 10^?8 M). The synthesis increased to 27 ng/10⁶ cells after 18 hours' incubation. These concentrations are similar to the ones of exogenous PGE₂ at which neonatal PML were slightly stimulated but the maternal cells were still suppressed. Preincubation for 18 h at 37°C decreased the PGE₂-induced suppression of the adult PML but did not change the response of the neonatal PML.     

抗肿瘤药物的研究Ⅲ. 数种锑胺羧螯合物对实验肿瘤的作用

1.锑胺羧螯合物是一种新型的抗肿瘤药物,应用Sb-26(EDTA-SbNa)、Sb-57(PDTA-SbNa)、Sb-66(HEDT-Sb)和Sb-71(ATA-Sb)分别为15—20、30—50、25—30和20—40毫克/公斤剂量时,均能显著地抑制小白鼠Ehrlich 腹水瘤的生长,平均延长生存时间4—22天,延长率36—147%.上述剂量对大白鼠Guerin 氏癌也有抑制作用,抑制率为58—70%.后3个药物,还能使小白鼠梭形细胞肉瘤腹水型的生存时间延长5—16天,延长率50—160%,其中以Sb-71的疗效最著.Sb-26、Sb-57、Sb-71、Sb-66对肉瘤180和AK 肉瘤及前3者对Ehrlich 固体瘤和淋巴白血病固体型的实验结果,除Sb-71对肉瘤180有抑制作用外,其他均无疗效.2.4 类锑化合物:3个(月弟)酸化合物(Sb-8,Sb-11和Sb-42)及1个酒石酸锑(Sb-15),与螯合的间苯二酚锑(Sb-64)和8羟基喹啉锑(Sb-85)各1个,对Ehrlich 腹水瘤的实验结果,均无明显疗效.3.小白鼠的急性半数致死量,Sb-57和Sb-71分别为131和62毫克/公斤,亚急性半数致死量分别为75和58毫克/公斤.     

Assessment of neutrophil chemotaxis and random migration in childhood. Comparison between leading-front and lower surface count methods

Neutrophil chemotaxis and random migration were studied in 65 healthy children and 18 normal adults. The method used, the leading-front technique, was more accurate and reproducible than the lower surface count method. Chemotaxis in children under 15 years differed from that in adults. This age effect was most pronounced in those less than 6 years, and particularly in those less than 2 years. When investigating chemotaxis in childhood, comparisons with age-matched controls should be made.     

同时测定乌梅中8种有机酸含量

目的：建立RP-HPLC同时测定乌梅中8种有机酸成分：草酸、酒石酸、苹果酸、抗坏血酸、乳酸、醋酸、柠檬酸和琥珀酸。方法：在C₁₈柱上,用（NH₄）H₂PO₄-H₃PO₄水溶液(pH 2.8)作流动相,紫外检测器检测（214 nm）,流动相流速为0.5 mL·min^-1。结果：分别建立了8种有机酸成分的回归方程。草酸、酒石酸、苹果酸、抗坏血酸、乳酸、醋酸、柠檬酸和琥珀酸的含量分别为1.29%,0.36%,1.82%,1.82%,2.09%,1.65%,16.0%,3.09%。结论：该方法操作简便,准确,快速,一次测定不超过10 min；不但可以作为中药乌梅有机酸成分的质量分析,也可用作为其他植物中有机酸的定量分析。     

高血压脑出血血肿周围组织血-脑屏障变化的动态观察

目的动态观察高血压脑出血血肿周围组织血-脑屏障的变化.方法对6例高血压脑出血患者实施立体定向血肿碎吸术,术中取血肿周围少许脑组织进行超微病理观察.结果血-脑屏障的损伤与出血时间的长短呈正比.脑出血后24h,可见星形胶质细胞肿胀,部分细胞崩解、坏死.毛细血管周围细胞足突肿胀,血-脑屏障损坏.72h,部分星形胶质细胞高度肿胀,细胞器溶解.毛细血管内皮细胞胞核增大,胞质突入管腔,内皮细胞间紧密连接消失.4～7d,星形细胞高度肿胀,胞质内充满水肿液,细胞器消失,细胞变性.毛细血管星形细胞足突明显肿胀,血管周围可见微小出血灶.结论血-脑屏障的变化与患者的预后有密切关系.     

几丁糖预防肘关节粘连的临床研究

目的　研究医用几丁糖预防肘关节粘连的临床作用。方法　对 2 6例肘关节僵硬患者进行手术松解 ,其中 12例术后关节腔内涂布 2 %几丁糖 ,另 14例术后不用几丁糖作为对照组 ,观察术后肘关节伸屈活动度改善程度以评定疗效。结果　 2 6例均获随访 ,随访时间 8～ 5 1个月 ,平均 2 4个月。几丁糖组术后肘关节平均活动度恢复到 92 .9°± 2 0 .9°,比术前增加 5 5 .0°± 15 .9°;对照组术后肘关节平均活动度恢复到 75 .4°± 17.5°,比术前增加38.2°± 11.9°。几丁糖组术后肘关节伸屈活动度增值明显大于对照组 ,有显著性差异 (P<0 .0 1)。结论　医用几丁糖具有减轻或预防肘关节松解术后再粘连的形成。     

胰头癌手术范围对预后的影响

目的: 探讨胰头癌切除范围对预后的影响。方法: 对比分析95例胰头癌患者中44例行经典胰十二指肠切除及51例行扩大胰十二指肠切除的生存期、手术并发症和死亡率等。结果: 扩大切除组和经典切除组术后1、3、5年存活率分别为72.5%、45%、17.5%和47.73%、19.35%、6.45%,两组间比较差异有显著性,扩大切除组1、3、5年存活率较经典切除组明显提高(P<0.05);两组手术并发症和死亡率 分 别 为 29.41%、5.88%和25%、4.55%,二者比较差异无显著性。结论: 扩大切除能改善胰头癌患者的预后。     

强直性脊柱炎后凸畸形矫形临床路径实施的变异程度分析

目的 通过分析强直性脊柱炎后凸畸形矫形临床路径实施的变异程度，研究该临床路径可能存在的不足并提出适当的改进方案。方法 收集自2012年1月至2013年12月的350例符合强直性脊柱炎后凸畸形矫形临床路径适应证的患者的资料，并根据变异的标准及类型进行统计分析。结果 350例病例中有290例发生变异，包括了16种变异情况，类型以负性变异、患者病情变化、不可控变异为主。结论 强直性脊柱炎后凸畸形矫形临床路径需要完善运行流程、制定详细的纳入和排除标准、同时加强社区医院及康复医院的相应诊疗过渡，从而更好地开展强直性脊柱炎后凸畸形矫形临床路径，最终提高患者医护质量、减少住院天数、降低住院费用。